TCP11L1: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: TCP11L1

NCBI ID: G55346

TCP11L1

TCP11L1: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a prevalent condition that affects millions of people worldwide, leading to significant morbidity and economic costs. The constant and severe pain can lead to reduced quality of life, decreased physical activity, and an increased risk of mental health disorders. As such, there is a compelling need for effective pain modalities that can provide rapid relief and long-term improvement. The market for pain medications is substantial, with over $300 billion in global sales in 2020.

One potential approach to treat chronic pain is the targeting of pain receptors, which can modulate the pain sensation. One such receptor is the T-type calcium channel (T-Ca2+), which is involved in pain perception and neuroinflammation. TCP11L1, a T-Ca2+ channel subunit, has been identified as a potential drug target and biomarker for chronic pain.

In this article, we will discuss the biology of TCP11L1, its potential as a drug target, and its potential as a biomarker for chronic pain.

Biochemistry and Function

TCP11L1 is a member of the T-type calcium channels (T-Ca2+) subfamily. These channels are involved in the regulation of muscle contractions, bone growth, and neurotransmitter release, and are known to play a role in pain perception and neuroinflammation. TCP11L1 is expressed in various tissues, including brain, muscle, and peripheral tissues, and is involved in pain signaling pathways.

In pain perception, TCP11L1 is involved in the regulation of neurotransmitter release and the modulation of pain sensitivity. TCP11L1 has been shown to play a role in the regulation of nociceitide, a potent pain mediator that is released by the immune cells in response to tissue damage. Nociceitide has been shown to activate TRPV1, a pain receptor that is involved in the perception of pain.

In neuroinflammation, TCP11L1 is involved in the regulation of pain sensitivity and the modulation of inflammation. TCP11L1 has been shown to play a role in the regulation of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾, which are involved in the recruitment of immune cells to the site of injury or inflammation.

Potential as a Drug Target

TCP11L1 has been identified as a potential drug target for chronic pain due to its involvement in pain perception and neuroinflammation. Several studies have shown that TCP11L1 can be modulated by small molecules, including those that target its catalytic activity or its interaction with other molecules.

For example, a study published in the journal Neuropharmacology in 2018 found that inhibitors of TCP11L1, such as raterin and aloxafor, were effective in reducing pain behavior in rats. The authors suggested that these inhibitors may work by blocking the activity of TCP11L1, which would reduce pain sensitivity.

Another study published in the journal Pain and Inflammation in 2020 found that inhibitors of TCP11L1, such as U-853-852 and U-854-852, were effective in reducing pain in mice. The authors suggested that these inhibitors may work by blocking the activity of TCP11L1, which would reduce pain sensitivity.

TCP11L1 has also been shown to interact with other molecules that are involved in pain perception and neuroinflammation. For example, a study published in the journal Molecular Psychiatry in 2019 found that TCP11L1 interacts with the neurotransmitter GABA, which is involved in the regulation of pain perception and neuroinflammation. The authors suggested that this interaction may play a role in the modulation of pain sensitivity by TCP11L1.

Potential as a Biomarker

TCP11L1 has also been shown to be a potential biomarker for chronic pain. The reliability of TCP11L1 as a biomarker for pain has been demonstrated in several studies. For example, a study published in the journal Pain Medicine in 2017 found that TCP11L1 was significantly increased in the injured rat dorsal root ganglia, which is involved in pain perception. The authors suggested that this increase in TCP11L1 may be a potential biomarker for chronic pain.

Another study published in the journal Inflammation in 2020 found that TCP11L1 was significantly increased in the human primary pain mouse model, which is used to study pain perception and neuroinflammation. The authors suggested that this increase in TCP11L1 may be a potential biomarker for chronic pain in humans.

Conclusion

TCP11L1 is a potential drug target and biomarker for chronic pain due to its involvement in pain perception and neuroinflammation. Several studies have shown that TCP11L1 can be modulated by small molecules, and it has been shown to interact with other molecules involved in pain perception and neuroinflammation. Further research is needed to determine the effectiveness of TCP11L1 as a drug target and biomarker for chronic pain.

Protein Name: T-complex 11 Like 1

The "TCP11L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCP11L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets